Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
Noosa News19 hours agoPilot left with life-threatening burns to his body as plane crashes to ground in Raglan, Queensland
-
Noosa News13 hours agoTeenage girl killed in house fire in Lawnton, Queensland as police probe potential e-bike link
-
Noosa News24 hours agoDiscover what makes Noosa Junction sparkle this Christmas
-
Noosa News23 hours agoBrisbane Lions beat Carlton by 35 points to set up third straight AFLW grand final against Kangaroos